Trials / Completed

CompletedNCT00602498

Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions

A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: 28 (actual)

Sponsor: Roxane Laboratories · Industry
Sex: All
Age: 18 Years – 45 Years
Healthy volunteers: Accepted

Summary

The objective of this study was the bioequivalence of a potential generic 500 mg clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin tablet, Biaxin® following a single 500 mg dose, administered with food.

Conditions

Infection

Interventions

Type	Name	Description
DRUG	Clarithromycin

Timeline

Start date: 2003-03-01
Primary completion: 2003-03-01
Completion: 2003-03-01
First posted: 2008-01-28
Last updated: 2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00602498. Inclusion in this directory is not an endorsement.